VISCHER advises CRISPR Therapeutics AG in an extension of the Series B financing with additional proceeds of 38 million. CRISPR Therapeutics AG with corporate seat in Basel is a bio-pharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into trans-formative medicines. This second, oversubscribed closing of the Series B financing, includes several new institutional investors and specialized healthcare funds. Participating investors in this round include Franklin Templeton Investments, New Leaf Venture Partners, funds advised by Clough Capital Partners L.P., Wellington Capital Management L.L.P., and other undisclosed funds specializing in life sciences. The VISCHER team was led by Dr. Matthias Staehelin (Partner) with Angelo Imperiale (Associate) both Corporate and Nadia Tarolli (Partner) Tax.